CytomX Therapeutics, Inc.

NasdaqGS:CTMX Voorraadrapport

Marktkapitalisatie: US$82.0m

CytomX Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 3/6

CytomX Therapeutics is de winst gegroeid met een gemiddeld jaarlijks percentage van 21.3%, terwijl de Biotechs industrie de winst jaarlijks groeide met 19%. De inkomsten zijn gegroeid met een gemiddelde van 10.3% per jaar.

Belangrijke informatie

21.3%

Groei van de winst

29.6%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei10.3%
Rendement op eigen vermogenn/a
Nettomarge9.3%
Volgende winstupdate07 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

Oct 26
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

Jul 15

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Jun 15
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

May 09
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

May 02

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 27
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

Mar 05
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Jan 19
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Nov 26
There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Nov 17
We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 29
Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Feb 13
Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

CytomX Therapeutics to cut workforce by about 40%

Jul 13

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Jul 06

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Jun 08
Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

Feb 10
Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

CytomX: Pullbacks Are Opportunities

Dec 14

CytomX: Solving A Critical Problem In The High-Value ADC Space

Sep 15

We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Aug 11
We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Opbrengsten en kosten

Hoe CytomX Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGS:CTMX Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 24120113183
31 Mar 24119173079
31 Dec 23101-13078
30 Sep 2395-103073
30 Jun 2379-423487
31 Mar 2368-713897
31 Dec 2253-9940107
30 Sep 2221-14942129
30 Jun 2227-14343127
31 Mar 2230-13240122
31 Dec 2137-11639114
30 Sep 2166-7239100
30 Jun 2166-643695
31 Mar 2167-613692
31 Dec 2068-6536113
30 Sep 2092-5436127
30 Jun 2085-6336131
31 Mar 2078-7637138
31 Dec 1927-13337132
30 Sep 1961-9937123
30 Jun 1962-9936123
31 Mar 1975-8336118
31 Dec 1860-8534104
30 Sep 1875-523296
30 Jun 1887-393098
31 Mar 1874-5027100
31 Dec 1772-432692
30 Sep 1751-582387
30 Jun 1730-622271
31 Mar 1724-512156
31 Dec 1615-592055
30 Sep 1611-571949
30 Jun 169-571845
31 Mar 168-501637
31 Dec 158-421328
30 Sep 158-361123
30 Jun 158-26818
31 Mar 156-24717
31 Dec 145-35728
31 Dec 131-19511

Kwaliteitswinsten: CTMX heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: CTMX is in het verleden winstgevend geweest.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: CTMX is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 21.3% per jaar laten groeien.

Versnelling van de groei: CTMX is het afgelopen jaar winstgevend geworden, waardoor de winstgroei moeilijk te vergelijken is met het 5-jarig gemiddelde.

Winst versus industrie: CTMX is het afgelopen jaar winstgevend geworden, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs -sector ( -2.3% ).


Rendement op eigen vermogen

Hoge ROE: De schulden van CTMX zijn groter dan de activa, dus het is lastig om het rendement op het eigen vermogen te berekenen.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden